RAMP3 is associated with macrophage-driven immune exclusion and promotes resistance to PD-1 blockade in breast cancer: integrated in vivo and single-cell transcriptomic analyses.
4 affiliations
- 1Department of Cardiovascular Research, School of Medicine, Shinshu University, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.
- 2Department of Cardiovascular Research, School of Medicine, Shinshu University, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan. [email protected].
- 3Department of Life Innovation, Institute for Biomedical Sciences, Shinshu University, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan. [email protected].
- 4Department of Life Innovation, Institute for Biomedical Sciences, Shinshu University, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.
Abstract
Background
Receptor activity-modifying protein 3 (RAMP3) has been implicated in stromal regulation in cancer. However, its role in tumor microenvironment (TME) remodeling and immune checkpoint resistance remains unclear. In this study, we aimed to define the role of RAMP3 in shaping the immunosuppressive TME and evaluate its potential as a therapeutic target to enhance immunotherapy responses.Methods
We used syngeneic mouse models of breast cancer with genetic manipulation of RAMP3 to investigate tumor progression, immune remodeling, and response to immune checkpoint blockade in vivo. Tumor growth, metastasis, and survival were evaluated. Single-cell RNA sequencing was performed on murine tumor tissues, and a publicly available spatial transcriptomic dataset was analyzed to characterize immune cell states and spatial organization within the TME. Human breast cancer datasets from The Cancer Genome Atlas were analyzed to assess the clinical relevance of RAMP3-associated immune signatures.Results
Our results suggest that RAMP3 contributed to the establishment of an immunosuppressive TME. In mouse models, RAMP3 deletion suppressed primary tumor growth, reduced lung metastasis, and improved survival. These effects were associated with a shift from M2-like tumor-associated macrophages to antigen-presenting macrophage states, increased CD8⁺ T cell infiltration, and reduced T cell exhaustion. Mechanistically, RAMP3 deficiency was associated with reduced IL-4/STAT6 signaling in macrophages and decreased expression of immunosuppressive genes, including the chemokine CCL8. Pharmacological inhibition of CCL synthesis phenocopied the effects of RAMP3 deficiency, and RAMP3 deficiency enhanced the efficacy of PD-1 blockade. Spatial transcriptomic analysis demonstrated co-localization of RAMP3 and CCL8 within the TME. In the TCGA-BRCA cohort, a higher weighted RAMP3/CD163/CD8A risk score was associated with poorer overall survival and remained significantly associated with overall survival in complete-case multivariable Cox models adjusted for clinicopathological variables.Conclusions
RAMP3 was identified as a potential regulator of the immunosuppressive TME and its functional impact was demonstrated in vivo. Integration with human clinical datasets supports further investigation of RAMP3 as a potential therapeutic target for overcoming resistance to immune checkpoint therapy in breast cancer.
Related
- A recurrent cancer-associated fibroblast/TGF-beta/endothelial barrier direction is associated with immune exclusion and checkpoint resistance in bladder cancer: a public multi-cohort transcriptomic study
- Integrated Transcriptomic and Single-Cell Analysis Reveals Shared Macrophage-Associated Inflammatory Signatures in MASLD/NAFLD and Rheumatoid Arthritis
- Integrated Transcriptomic Analysis Identifies a Ferroptosis-Related Gene Signature Underlying Macrophage Heterogeneity and Immune Dysregulation in Rheumatoid Arthritis Synovium
- Longitudinal transcriptomic analysis reveals adaptive transcript usage remodeling associated with PARP inhibitor resistance
- Integrated Transcriptomic Analysis Identifies ENO3 as a Candidate Lactate Metabolism‐Associated Biomarker in Colorectal Cancer Metastasis
BibTeX
@article{zhang2026ramp3,
title = {{RAMP3 is associated with macrophage-driven immune exclusion and promotes resistance to PD-1 blockade in breast cancer: integrated in vivo and single-cell transcriptomic analyses.}},
author = {Yan Zhang and Megumu Tanaka and Takayuki Sakurai and Akiko Kamiyoshi and Yuka Ichikawa-Shindo and Qianqian Guo and Ken Hoshiyama and Peixuan Li and Jiake Li and Jun Duan and Marina Hayashi and Kensuke Kai and Yunlu Zhao and Kun Dai and Takayuki Shindo},
journal = {Journal of translational medicine},
year = {2026},
month = sep,
doi = {10.1186/s12967-026-09001-4},
url = {https://europepmc.org/article/MED/42958394},
note = {CC BY},
}
RIS
TY - JOUR
TI - RAMP3 is associated with macrophage-driven immune exclusion and promotes resistance to PD-1 blockade in breast cancer: integrated in vivo and single-cell transcriptomic analyses.
AU - Yan Zhang
AU - Megumu Tanaka
AU - Takayuki Sakurai
AU - Akiko Kamiyoshi
AU - Yuka Ichikawa-Shindo
AU - Qianqian Guo
AU - Ken Hoshiyama
AU - Peixuan Li
AU - Jiake Li
AU - Jun Duan
AU - Marina Hayashi
AU - Kensuke Kai
AU - Yunlu Zhao
AU - Kun Dai
AU - Takayuki Shindo
PY - 2026
DA - 2026/09/26
JO - Journal of translational medicine
DO - 10.1186/s12967-026-09001-4
UR - https://europepmc.org/article/MED/42958394
AB - Background Receptor activity-modifying protein 3 (RAMP3) has been implicated in stromal regulation in cancer. However, its role in tumor microenvironment (TME) remodeling and immune checkpoint resistance remains unclear. In this study, we aimed to define the role of RAMP3 in shaping the immunosuppressive TME and evaluate its potential as a therapeutic target to enhance immunotherapy responses.Methods We used syngeneic mouse models of breast cancer with genetic manipulation of RAMP3 to investigate tumor progression, immune remodeling, and response to immune checkpoint blockade in vivo. Tumor growth, metastasis, and survival were evaluated. Single-cell RNA sequencing was performed on murine tumor tissues, and a publicly available spatial transcriptomic dataset was analyzed to characterize immune cell states and spatial organization within the TME. Human breast cancer datasets from The Cancer Genome Atlas were analyzed to assess the clinical relevance of RAMP3-associated immune signatures.Results Our results suggest that RAMP3 contributed to the establishment of an immunosuppressive TME. In mouse models, RAMP3 deletion suppressed primary tumor growth, reduced lung metastasis, and improved survival. These effects were associated with a shift from M2-like tumor-associated macrophages to antigen-presenting macrophage states, increased CD8⁺ T cell infiltration, and reduced T cell exhaustion. Mechanistically, RAMP3 deficiency was associated with reduced IL-4/STAT6 signaling in macrophages and decreased expression of immunosuppressive genes, including the chemokine CCL8. Pharmacological inhibition of CCL synthesis phenocopied the effects of RAMP3 deficiency, and RAMP3 deficiency enhanced the efficacy of PD-1 blockade. Spatial transcriptomic analysis demonstrated co-localization of RAMP3 and CCL8 within the TME. In the TCGA-BRCA cohort, a higher weighted RAMP3/CD163/CD8A risk score was associated with poorer overall survival and remained significantly associated with overall survival in complete-case multivariable Cox models adjusted for clinicopathological variables.Conclusions RAMP3 was identified as a potential regulator of the immunosuppressive TME and its functional impact was demonstrated in vivo. Integration with human clinical datasets supports further investigation of RAMP3 as a potential therapeutic target for overcoming resistance to immune checkpoint therapy in breast cancer.
SN - 1479-5876
ER -